主页 > 医药科学 >

【文摘发布】来自"Cochrane 数据库系统评价"的

Titlie:Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients.
Author:Shilliday I, Sherif M.
Source:Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003421
BACKGROUND: The incidence of delayed graft function in cadaveric grafts has increased over the last few years due in part to the large demand for cadaveric kidneys necessitating the use of kidneys from marginal donors. Calcium channel blockers have the potential to reduce the incidence of post-transplant acute tubular necrosis (ATN) if given in the peri-operative period. However, there is controversy surrounding their use in this situation with no consensus as to their efficacy. OBJECTIVES: To evaluate the benefits and harms of using calcium channel blockers in the peri-transplant period in patients at risk of ATN following cadaveric kidney transplantation. SEARCH STRATEGY: We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library) MEDLINE (from 1966) and EMBASE (from 1980). The Trials Search Coordinator was contacted to develop the search strategy.Date of last search: January 2007 SELECTION CRITERIA: Randomised controlled trials comparing calcium channel blockers given in the peri-transplant period with controls were included. Quasi-randomised trials were excluded. DATA COLLECTION AND ANALYSIS: Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. Dichotomous outcomes are reported as relative risk (RR) and measurements on continuous scales are reported as mean differences (WMD) with 95% confidence intervals (CI). MAIN RESULTS: Thirteen trials (724 participants) were suitable for inclusion. Treatment with calcium channel blockers in the peri-transplant period was associated with a significant decrease in the incidence of post-transplant ATN (RR 0.62, 95% CI 0.46 to 0.85) and delayed graft function (RR 0.55, 95% CI 0.42 to 0.73). There was no difference between control and treatment groups in graft loss, mortality, requirement for haemodialysis. There was insufficient information to comment on adverse events. AUTHORS' CONCLUSIONS: These results suggest that calcium channel blockers given in the peri-operative period may reduce the incidence of ATN post-transplantation. The result should be treated with caution due to the heterogeneity of the trials which made comparison of studies and pooling of data difficult. 本人认领该文编译,48小时后若未提交译文,请其他战友自由认领 Titlie:Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients.钙通道阻断剂预防肾移植受体急性肾小管坏死
Author:Shilliday I, Sherif M.
Source:Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003421
BACKGROUND: The incidence of delayed graft function in cadaveric grafts has increased over the last few years due in part to the large demand for cadaveric kidneys necessitating the use of kidneys from marginal donors.背景:近年来,部分由于尸体肾的大量需求迫使对边缘捐献者肾脏的使用导致迟发移植物功能(障碍)的发生有所增加。 Calcium channel blockers have the potential to reduce the incidence of post-transplant acute tubular necrosis (ATN) if given in the peri-operative period. 如果在围手术期给药钙通道阻断剂有减少移植后急性肾小管坏死(ATN)的可能性。However, there is controversy surrounding their use in this situation with no consensus as to their efficacy. 然而因对它的功效尚没有一致意见,在此种情况下围绕它的使用尚有争议.OBJECTIVES: To evaluate the benefits and harms of using calcium channel blockers in the peri-transplant period in patients at risk of ATN following cadaveric kidney transplantation.目的: 评估尸体肾移植面临ATN风险患者围移植手术期使用钙通道阻断剂的益处和害处。SEARCH STRATEGY: We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library) MEDLINE (from 1966) and EMBASE (from 1980). 搜索策略:我们搜索了Cochrane肾组专门的记录,对照试验的Cochrane中心记录,MEDLINE(自1966)和EMBASE(1980)The Trials Search Coordinator was contacted to develop the search strategy.与试验搜索协调者交流意见来完善搜索策略。Date of last search: January 2007 上次搜索日期:2007年1月。SELECTION CRITERIA: Randomised controlled trials comparing calcium channel blockers given in the peri-transplant period with controls were included.选择标准:比较对照和钙通道阻断剂围移植手术期给药的随机对照试验入选。半随机对照试验被排除。 Quasi-randomised trials were excluded. DATA COLLECTION AND ANALYSIS: Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. 数据收集和分析:由两名评论者分别提取数据并进行质量评估,有不同意见时讨论解决。Dichotomous outcomes are reported as relative risk (RR) and measurements on continuous scales are reported as mean differences (WMD) with 95% confidence intervals (CI).二分式结果以相对风险性报告,连续标度的测量结果以95%可信区间均值标准差报告。 MAIN RESULTS: Thirteen trials (724 participants) were suitable for inclusion.主要结果:13个试验(724 名参与者) 适合选入。 Treatment with calcium channel blockers in the peri-transplant period was associated with a significant decrease in the incidence of post-transplant ATN (RR 0.62, 95% CI 0.46 to 0.85) and delayed graft function (RR 0.55, 95% CI 0.42 to 0.73). 围移植手术期使用钙通道阻断剂治疗与移植术后ATN (RR 0.62, 95% CI 0.46 to 0.85)和迟发移植物功能(障碍)(RR 0.55, 95% CI 0.42 to 0.73)发生显著减少相关。There was no difference between control and treatment groups in graft loss, mortality, requirement for haemodialysis. 对照和治疗组在移植物丢失,死亡率和是否需要血液透析方面没有差异。There was insufficient information to comment on adverse events. A没有足够的信息对不良事件下结论。UTHORS' CONCLUSIONS: These results suggest that calcium channel blockers given in the peri-operative period may reduce the incidence of ATN post-transplantation. The result should be treated with caution due to the heterogeneity of the trials which made comparison of studies and pooling of data difficult.作者结论:结果显示钙通道阻断剂围手术期给药可能减少移植术后ATN的发生。此结果应谨慎对待因为试验的不均一性导致研究和数据库之间比较有困难。

阅读本文的人还阅读:

冠心病介入治疗临床试验

生殖道感染危险因素评价

系统性红斑狼疮与妊娠

【bio-news】Nature: 探索生

干细胞重建神经系统

作者:admin@医学,生命科学    2011-06-01 14:36
医学,生命科学网